Interim report January-September 2009 Third quarter 2009 • Net sales decreased by 2 percent to 90.6 MSEK (92.3). At comparable exchange rates sales decreased by 13 percent. • The operating result amounted to 2.0 MSEK (7.0). • The result after tax amounted to 1.4 MSEK (6.6). • Earnings per share amounted to 0.01 SEK (0.14). • Net cash at September 30, 2009 amounted to 326.6 MSEK. • As a part of Biotage's buy-back program 158,779 own shares were repurchased at a total value of 1.1 MSEK, i.e. an average share price of 6.93 SEK. • The cash flow from operating activities amounted to 4.5 MSEK (13.0). January - September 2009 • Net sales increased by 7 percent to 294.6 MSEK (276.3). At comparable exchange rates sales decreased by 11 percent. • The operating result amounted to -13.7 MSEK (10.8). Before restructuring costs the operating result amounted to 7.5 MSEK (10.8). • The result after tax amounted to -14.5 MSEK (8.8). • Earnings per share amounted to -0.16 SEK (0.38). • Net cash at September 30, 2009 amounted to 326.6 MSEK. • Dividends to shareholders have been paid to the amount of 17.7 MSEK. • As a part of Biotage's buy-back program 158,779 own shares were repurchased at a total value of 1.1 MSEK. • The cash flow from operating activities amounted to 21.2 MSEK (10.2). For further information, please contact: Torben Jörgensen, president and CEO, phone: +46 707 49 05 84 Mats-Olof Wallin, CFO, phone: +46 705 93 52 73 About Biotage Biotage offers solutions, knowledge and experience in the areas of analytical chemistry and medicinal chemistry. The customers include the world's largest pharmaceutical and biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has subsidiaries in the US, UK and Japan. Biotage has 270 employees and had sales of 385.3 MSEK in 2008. Biotage is listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website: www.biotage.com
Interim report January-September 2009
| Source: Biotage AB
Attachments
